Beam Therapeutics (BEAM *) Stock Overview
A biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
BEAM * Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Beam Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$520.00 |
| 52 Week High | US$604.00 |
| 52 Week Low | US$309.00 |
| Beta | 2.17 |
| 1 Month Change | -13.91% |
| 3 Month Change | n/a |
| 1 Year Change | 1.96% |
| 3 Year Change | -30.67% |
| 5 Year Change | n/a |
| Change since IPO | -35.48% |
Recent News & Updates
Recent updates
Shareholder Returns
| BEAM * | MX Biotechs | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | 2.0% | 0% | 0% |
Return vs Industry: BEAM * underperformed the MX Biotechs industry which returned 16.6% over the past year.
Return vs Market: BEAM * underperformed the MX Market which returned 18.5% over the past year.
Price Volatility
| BEAM * volatility | |
|---|---|
| BEAM * Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: BEAM *'s share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine BEAM *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 511 | John Evans | beamtx.com |
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs.
Beam Therapeutics Inc. Fundamentals Summary
| BEAM * fundamental statistics | |
|---|---|
| Market cap | Mex$43.92b |
| Earnings (TTM) | -Mex$1.44b |
| Revenue (TTM) | Mex$2.51b |
Is BEAM * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BEAM * income statement (TTM) | |
|---|---|
| Revenue | US$139.74m |
| Cost of Revenue | US$409.62m |
| Gross Profit | -US$269.87m |
| Other Expenses | -US$189.88m |
| Earnings | -US$79.99m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.81 |
| Gross Margin | -193.12% |
| Net Profit Margin | -57.24% |
| Debt/Equity Ratio | 0% |
How did BEAM * perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/21 01:04 |
| End of Day Share Price | 2026/02/24 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Beam Therapeutics Inc. is covered by 22 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| William Pickering | Bernstein |
| Alec Stranahan | BofA Global Research |
| Whitney Ijem | Canaccord Genuity |